Somesh Nigam

Somesh Nigam

Auto-generated profile, based on publicly available information

Somesh Nigam

Blue Cross Blue Shield of Louisiana, Baton Rouge, LA, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2020 in Journal of Stroke
Verified
Journal Article
Open access
PDF file
YSYun Shen
Yun Shen
LSLizheng Shi
Lizheng Shi
ENElizabeth Nauman
Elizabeth Nauman
PKPeter Katzmarzyk
Peter Katzmarzyk
EPEboni Price-Haywood
Eboni Price-Haywood
GHGang Hu
Gang Hu
Background and Purpose The association between hemoglobin A1c (HbA1c) and stroke risk along with its subtypes is rarely reported. We aimed to investigate the association between HbA1c and the risk of incident stroke in patients with type 2 diabetes based on real world data from three healthcare systems.Methods We performed a retrospective cohort study of 27,113 African Americans and 40,431 whites with type 2 diabetes. Demographic, anthropometric, laboratory, and medication information were abstracted from the National Patient-Centered Clinical Research Network common data model. Incident stroke events including both ischemic and hemorrhagic stroke were defined.Results During a mean follow-up period of 3.79±1.68 years, 7,735 patients developed stroke (6,862 ischemic and 873 hemorrhagic). Multivariable-adjusted hazard ratios across levels of HbA1c at baseline (<6.0%, 6.0% to 6.9% [reference group], 7.0% to 7.9%, 8.0% to 8.9%, 9.0% to 9.9%, and ≥10%) were 1.07, 1.00, 1.13, 1.23, 1.27, and 1.37 (Ptrend <0.001) for total stroke, 1.02, 1.00, 1.13, 1.20, 1.24, and 1.35 (Ptrend <0.001) for ischemic stroke, and 1.40, 1.00, 1.14, 1.47, 1.47, and 1.51 (Ptrend=0.002) for hemorrhagic stroke. When we used an updated mean value of HbA1c, the U-shaped association of HbA1c with stroke risk did not change. This U-shaped association was consistent among patients of different subgroups. The U-shaped association was more pronounced among patients taking antidiabetic, lipid-lowering, and antihypertensive medications compared with those without these medications.Conclusions These data suggest that diabetes management may have to be individualized according to the guideline recommendations rather than intensively attempting to lower HbA1c.

13 February 2020 in Journal of Medical Economics
Verified
Journal Article
Open access
MLM. Liu
M. Liu
XYX. Yuan
X. Yuan
JOJ. Ouyang
J. Ouyang
JCJ. Chaisson
J. Chaisson
TBT. Bergeron
T. Bergeron
SNS. Nigam
S. Nigam
Aims: Chronic diseases impose a substantial healthcare burden. This study sought to evaluate the clinical and economic impact of new disease management (DM) programs, targeting 4 major chronic disease groups: diabetes, coronary heart disease (CHD)/hypertension (HTN), asthma/chronic obstructive pulmonary disease (COPD), and congestive heart failure (CHF)/chronic kidney disease (CKD). Materials and Methods: Between March 1, 2015, and February 28, 2018, members with Blue Cross Blue Shield of Louisiana insurance were contacted and enrolled in a DM program if they were aged 18 years through 64 years, eligible for a DM program, and had not been previously enrolled in a DM program. Active enrollees of a DM program (‘IN’ group) were compared to members who were not yet enrolled (‘OUT’ group). Average per member per month (PMPM) costs were aggregated annually to document any descriptive trends. Multivariable model estimates were used to compare PMPM costs for all IN subjects and all OUT subjects. Total medical savings were evaluated for the following time intervals: 1-12 months, 13-24 months, and 25-36 months. Results: For all 4 DM programs, average costs PMPM trended upward over time for the OUT cohort, while they remained relatively stable for the IN cohort. Some evidence also showed that DM programs improved clinical outcomes, such as hemoglobin A1c values. A difference in difference analysis showed PMPM savings for all 4 programs combined of $31.61, $50.45, and $53.72 after 1, 2, and 3 years, respectively. Multivariable modeling results showed total savings after 3 years of $14,460,174 for all DM programs combined. Limitations: Although multivariable models adjusted for several clinical, demographic, and economic characteristics; it is possible that some important confounders were missing due to lack of data. Conclusions: DM programs implemented to control diabetes, CHD/HTN, CHF/CKD, and asthma/COPD are cost-effective and show some evidence of improved clinical outcomes.

10 June 2023 in Value in Health
Verified
Journal Article
Closed access
MKM. Kiggans
M. Kiggans
RZR. Zhang
R. Zhang
TET. Evans
T. Evans
TBT. Bergeron
T. Bergeron
ELE. Lucas
E. Lucas
SNS. Nigam
S. Nigam

25 June 2022 in Value in Health
Verified
Journal Article
Closed access
CMCong Meili
Cong Meili
BMB Mohundro
B Mohundro
MCM Carby
M Carby
MFM Ford
M Ford
MLM Liu
M Liu
SNS Nigam
S Nigam

25 June 2022 in Value in Health
Verified
Journal Article
Closed access
HZH Zhang
H Zhang
ELE Lucas
E Lucas
MKM Kiggans
M Kiggans
YZY Zhang
Y Zhang
BVB Vicidomina
B Vicidomina
SNS Nigam
S Nigam